Skip to main content Go body Go Menu
G03-8236672469

ImmuneOncia, a US Joint Venture of Yuhan, Attracted $ 40 Million Investment.

NSP NEWS AGENCY, By soon ki Lee Journali, 2019-02-14 09:34 END7
#Yuhan #ImmuneOncia #Sorrento #$40million investmen

(Seoul=NSP News Agency) soon ki Lee Journalist = ImmuneOncia Therapeutics Inc., which is a joint venture between Yuhan and Sorrento Therapeutics Inc., and a US biotechnology company, succeeded in attracting $ 40 million in funds.

ImmuneOncia came to accelerate the clinical study of IMC-001, the immune anticancer agent, with this fund-raising. In addition, it plans to take part in IPO in 2021.

ImmuneOncia was founded in 2016 and is specialized in immunology.

G03-8236672469

ParatusSP, which invested in ImmuneOncia, came to account for 29.3 percent of equity in ImmuneOncia, Yuhan reduced to 36.1 percent of equity in it, and Sorrento has 34.6 percent of equity in ImmuneOncia.

NSP News Agency/NSP TV soon ki Lee Journalist, s8789@nspna.com
Copyright ⓒ Korea's economic news agency NSP NEWS·NSP TV. All rights reserved-Redistribution Prohibited.